Daniel Reibert
Papers
1
Total Citations
17
H-Index
1
About
Daniel Reibert is a pioneering researcher at the forefront of advanced therapeutic medicinal products (ATMPs) and automated cell therapy manufacturing. His work addresses a critical bottleneck in regenerative medicine: the transition from costly, high-risk manual cell expansion to scalable, clinically-compliant production. Reibert’s most cited paper, “Needle to needle robot‑assisted manufacture of cell therapy products” (2022, 17 citations), introduces a groundbreaking fully robotic platform that automates the entire workflow—from raw material to final product—ensuring GMP-grade quality and reproducibility. This innovation promises to democratize access to life-saving cell therapies by drastically reducing production costs and risks. By integrating robotics with bioprocess engineering, Reibert is shaping the future of personalized medicine, enabling large-volume manufacturing for previously untreatable diseases. His work stands as a key achievement in bridging the gap between laboratory discovery and clinical reality, making him a vital contributor to the next generation of therapeutic manufacturing.
Research Focus
Key Achievements
Top Papers
- 1